key: cord-0777719-nvev577g
authors: Deokar, Kunal; Shadrach, Benhur Joel; Asfahan, Shahir; Chawla, Gopal; Agarwal, Mehul; Dutt, Naveen; Niwas, Ram; S, Aneesa Shahul
title: Low dose radiotherapy for COVID pneumonia: Irradiate to Eradicate – Will it be possible?
date: 2020-11-10
journal: Acta Biomed
DOI: 10.23750/abm.v92i1.10369
sha: 51e8d9b152f2a44122d72b6c8ab1c12461adb3b4
doc_id: 777719
cord_uid: nvev577g

.

To The Editor, The novel corona virus (SARS-CoV-2) which emerged in Wuhan, China continues to create havoc throughout the world. The management of Covid-19 is rapidly evolving. No cure has been found till now, although several avenues are being explored. If we look back into the 20 th century, low dose radiotherapy (LDRT) was used to treat a variety of infections like gas gangrene, carbuncles, furuncles, inner ear infections, sinusitis, and pneumonia. Desperate time calls for desperate measure and hence the safety and efficacy of this therapy for COVID-19 pneumonia is currently being explored.

There are many ways via which radiation therapy has been postulated to work in pneumonia. First is by exerting an anti-inflammatory effect, second by inducing metabolic rewiring of the host cells, and third by virtue of inducing the "abscopal effect". Phenotypically, macrophages are of two types -M1 and M2. M1 macrophages promote Th1 polarization of CD4 cells while M2 macrophages exert an anti-inflammatory effect by inducing production of anti-inflammatory mediators such as IL-4, IL-10, and TGF-β (1). The pathogenesis of SARS-CoV-2 involves uncontrolled inflammation secondary to the cytokine storm. Low dose radiotherapy polarizes the macrophages to a M2 "anti-inflammatory" phenotype and thus will help in controlling the hyperinflammatory state in COVID-19. Viruses are known to hijack the host cell machinery and utilise glucose and glutamine for replication (2) . Low dose radiotherapy increases the oxygen metabolism of cells, thus increasing metabolic competition and limiting viral replication. Klug et al showed that low dose radiation mobilises macrophages and T-cells into the irradiated area, thus orchestrating effective immune response against the virus (3).

LDRT has been used historically for the treatment of bacterial and viral pneumonia. In a review of 15 papers with total 863 patients of bacterial and viral pneumonia, Calabrese et al showed that low dose radiotherapy was associated with promising results (4). However, most of the papers were case series, case reports and studies with no control arm, resulting in a very lowquality evidence. Till date, there are no randomised controlled trials on the use of LDRT in SARS-CoV-2 pneumonia. We found twelve clinical trials registered on clinical trials.gov and WHO International Registry of Clinical Trials Platform (IRCTP) which will study the safety and efficacy of radiotherapy in COVID-19. They are summarised in table 1. The patients recruited will be moderate to severe cases of COVID-19 and the dose used will be 0.5-1 Gy in a single fraction to both the lungs. The results of an interim analysis of a clinical trial NCT04366791 are available on a preprint server (5) . Five oxygen dependent, lab confirmed cases of COVID-19 with bilateral pneumonia received single fraction of low dose radiation to both the lungs. Mean age of the patients was 90 years (range 64-94 years). Mean time to clinical recovery was 35 hours post radiation. Four patients showed radiological improvement within 24 hours. Three patients could be weaned off supplemental oxygen within 24 hours while one patient could be weaned off after 96 hours. However, the results are not yet peer reviewed. Based on invitro, in vivo and human data, a single dose of 0.1-0.5 Gy has been advocated for use in COVID pneumonia (6) . While COVID-19 itself is associated with coagulopathy, there is a potential concern that radiotherapy may worsen it. Radiation induced coagulopathy superimposed on COVID induced coagulopathy can have disastrous consequences. However, it is unlikely to occur at a single low dose which will be administered to patients of COVID-19. Lymphocytes are one of the most radiosensitive mammalian cells. Radiation therapy can deplete lymphocytes resulting in exacerbation of already existing lymphocytopenia in these patients. As only low dose is used, the possibility of long-term adverse effects like cancer is minimal.

LDRT can be considered a promising option as it seems to confer a modest theoretical benefit due to its varied mechanisms. Whether these theoretical benefits will translate into better clinical outcomes is still to be known. At present, there is paucity of evidence regarding its safety and efficacy. Therefore, it is advised to await the results of various trials and refinement of the existing evidence before incorporating this therapy in the management of Covid-19 pneumonia.

Role of Human Macrophage Polarization in Inflammation during Infectious Diseases

Viral hijacking of cellular metabolism

Low-dose irradiation programs macrophage differentiation to an iNOS + /M1 phenotype that orchestrates effective T cell immunotherapy

How radiotherapy was historically used to treat pneumonia: could it be useful today?

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial

Low dose radiation therapy as a potential life-saving treatment for COVID-19-induced acute respiratory distress syndrome

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.